Mast cells and cutaneous malignancies

被引:140
作者
Ch'ng, S
Wallis, RA
Yuan, L
Davis, PF
Tan, ST
机构
[1] Hutt Hosp, Wellington Reg Plast Maxillofacial & Burns Unit, Wellington, New Zealand
[2] Wellington Sch Med & Hlth Sci, Dept Med, Wellington, New Zealand
[3] Environm Risk Management Author, Wellington, New Zealand
关键词
mast cell; cutaneous malignancy; skin cancer; immunosuppression; angiogenesis; extracellular matrix;
D O I
10.1038/modpathol.3800474
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Mast cells accumulate around cutaneous malignancies. Current evidence suggests that mast cells contribute to the tumorigenesis of cutaneous malignancies through four mechanisms. ( 1) Immunosuppression: Ultraviolet-B radiation, the most important initiator of cutaneous malignancies, activates mast cells. Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers. These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. ( 2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma. Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix. Mast cell proteases reorganize the stroma to facilitate endothelial cell migration. As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. ( 3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. ( 4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells. Current evidence supports an accessory role for mast cells in the development and progression of cutaneous malignancies. Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
引用
收藏
页码:149 / 159
页数:11
相关论文
共 103 条
[91]   ULTRASTRUCTURAL MORPHOMETRIC ANALYSIS OF HUMAN MAST-CELLS IN NORMAL SKIN AND PATHOLOGICAL CUTANEOUS LESIONS [J].
THARP, MD ;
GLASS, MJ ;
SEELIG, LL .
JOURNAL OF CUTANEOUS PATHOLOGY, 1988, 15 (02) :78-83
[92]   Mast cells: the JEKYLL and HYDE of tumor growth [J].
Theoharides, TC ;
Conti, P .
TRENDS IN IMMUNOLOGY, 2004, 25 (05) :235-241
[93]   DIFFERENTIAL RELEASE OF SEROTONIN AND HISTAMINE FROM MAST-CELLS [J].
THEOHARIDES, TC ;
BONDY, PK ;
TSAKALOS, ND ;
ASKENASE, PW .
NATURE, 1982, 297 (5863) :229-231
[94]  
Tóth T, 2000, HUM PATHOL, V31, P955
[95]   Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival [J].
Ugurel, S ;
Rappl, G ;
Tilgen, W ;
Reinhold, U .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :577-583
[96]   Current therapy of cutaneous melanoma [J].
Wagner, JD ;
Gordon, MS ;
Chuang, TY ;
Coleman, JJ .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2000, 105 (05) :1774-1799
[97]  
WALLIS R, 2004, SCIENCE, P1
[98]   ULTRAVIOLET-B IRRADIATION OF SKIN INDUCES MAST-CELL DEGRANULATION AND RELEASE OF TUMOR-NECROSIS-FACTOR-ALPHA [J].
WALSH, LJ .
IMMUNOLOGY AND CELL BIOLOGY, 1995, 73 (03) :226-233
[99]   Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth [J].
Wang, YP ;
Becker, D .
NATURE MEDICINE, 1997, 3 (08) :887-893
[100]   cis-urocanic acid induces mast cell degranulation and release of preformed TNF-α:: A possible mechanism linking UVB and cis-urocanic acid to immunosuppression of contact hypersensitivity [J].
Wille, JJ ;
Kydonieus, AF ;
Murphy, GF .
SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY, 1999, 12 (1-2) :18-27